VF
TCRX icon

Virtu Financial’s TScan Therapeutics TCRX Stock Holding History

Virtu Financial’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
+18,140
New +$19.4K ﹤0.01% 1405
2025
Q4 		– Sell
-60,480
Closed -$110K – 2221
2025
Q3 		$110K Buy
60,480
+49,092
+431% +$87K 0.01% 1031
2025
Q2 		$17K Buy
11,388
+365
+3% +$527 ﹤0.01% 1271
2025
Q1 		$15K Buy
+11,023
New +$23.8K ﹤0.01% 1144
2024
Q1 		– Sell
-18,418
Closed -$107K – 2083
2023
Q4 		$107K Buy
+18,418
New +$84.3K 0.01% 1017

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Virtu Financial's TCRX Position: Q1 2026 in Review

Virtu Financial opened a new position in TScan Therapeutics (TCRX) in Q1 2026: 18,140 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #1405 among its holdings. This is a return to the name: Virtu Financial previously reported a position in TCRX as recently as Q3 2025.

Virtu Financial first reported a position in TCRX in Q4 2023 and has held it in 5 quarters since. The position peaked at $110K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Virtu Financial held 18,140 shares of TScan Therapeutics worth $18K as of Q1 2026.
  • TScan Therapeutics was a new Virtu Financial position in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1405 holding.
  • Virtu Financial first reported a position in TScan Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • Virtu Financial's TScan Therapeutics position peaked at $110K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.